Ticker
$PYPD
1 article on $PYPD
kxco sentiment
100% bull0% bear
- $INOBullish
KXCO's FDA Ontology Is Two for Two on FDA Decisions
The FDA has decided two filings on KXCO's FDA board since the board began ranking them, and on my scorecard the board got both right. It ranked Inovio's INO-3107 first and the FDA approved it on 30 October; Inovio moved +149.1% net of the sector. It gave Summit's ivonescimab no call, and Summit announced the FDA's refusal on 15 November; Summit fell 16.5%. KXCO's record held the FDA's survival warning before the refusal was announced.
Shayne Heffernan12 min